These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 31415061)

  • 1. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.
    Wang F; Zhao Q; Wang YN; Jin Y; He MM; Liu ZX; Xu RH
    JAMA Oncol; 2019 Oct; 5(10):1504-1506. PubMed ID: 31415061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
    Rosner G; Gluck N; Carmi S; Bercovich D; Fliss-Issakov N; Ben-Yehoyada M; Aharon-Caspi S; Kellerman E; Strul H; Shibolet O; Kariv R
    Dis Colon Rectum; 2018 Sep; 61(9):1073-1079. PubMed ID: 30086056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis.
    Valle L; Hernández-Illán E; Bellido F; Aiza G; Castillejo A; Castillejo MI; Navarro M; Seguí N; Vargas G; Guarinos C; Juarez M; Sanjuán X; Iglesias S; Alenda C; Egoavil C; Segura Á; Juan MJ; Rodriguez-Soler M; Brunet J; González S; Jover R; Lázaro C; Capellá G; Pineda M; Soto JL; Blanco I
    Hum Mol Genet; 2014 Jul; 23(13):3506-12. PubMed ID: 24501277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
    Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
    Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Allelic Variants of the
    LA P; D B; Z D; J G; E M
    Balkan J Med Genet; 2017 Dec; 20(2):83-88. PubMed ID: 29876237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes.
    Golmard L; Golmard JL; Stoppa-Lyonnet D
    JAMA Oncol; 2020 Apr; 6(4):588-589. PubMed ID: 32134431
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes.
    Rousseau B; Vidal J; Diaz LA
    JAMA Oncol; 2020 Apr; 6(4):589-590. PubMed ID: 32134429
    [No Abstract]   [Full Text] [Related]  

  • 8. Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps.
    Elsayed FA; Tops CMJ; Nielsen M; Ruano D; Vasen HFA; Morreau H; J Hes F; van Wezel T
    Mol Genet Genomic Med; 2019 Apr; 7(4):e00603. PubMed ID: 30827058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes-Reply.
    Wang F; Zhao Q; Xu RH
    JAMA Oncol; 2020 Apr; 6(4):590. PubMed ID: 32134432
    [No Abstract]   [Full Text] [Related]  

  • 10. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.
    Esteban-Jurado C; Giménez-Zaragoza D; Muñoz J; Franch-Expósito S; Álvarez-Barona M; Ocaña T; Cuatrecasas M; Carballal S; López-Cerón M; Marti-Solano M; Díaz-Gay M; van Wezel T; Castells A; Bujanda L; Balmaña J; Gonzalo V; Llort G; Ruiz-Ponte C; Cubiella J; Balaguer F; Aligué R; Castellví-Bel S
    Oncotarget; 2017 Apr; 8(16):26732-26743. PubMed ID: 28423643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mutations and phenotypic associations identified through APC, MUTYH, NTHL1, POLD1, POLE gene analysis in Indian Familial Adenomatous Polyposis cohort.
    Khan N; Lipsa A; Arunachal G; Ramadwar M; Sarin R
    Sci Rep; 2017 May; 7(1):2214. PubMed ID: 28533537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
    Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
    Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients.
    Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
    Thorac Cancer; 2020 Jun; 11(6):1647-1654. PubMed ID: 32342665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of exogenous MSH6 and POLD1 expression on the mutation rate of the HPRT locus in a human colon cancer cell line with mutator phenotype, DLD-1.
    Yabuta T; Shinmura K; Yamane A; Yamaguchi S; Takenoshita S; Yokota J
    Int J Oncol; 2004 Mar; 24(3):697-702. PubMed ID: 14767555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POLD1 Germline Mutations in Patients Initially Diagnosed with Werner Syndrome.
    Lessel D; Hisama FM; Szakszon K; Saha B; Sanjuanelo AB; Salbert BA; Steele PD; Baldwin J; Brown WT; Piussan C; Plauchu H; Szilvássy J; Horkay E; Högel J; Martin GM; Herr AJ; Oshima J; Kubisch C
    Hum Mutat; 2015 Nov; 36(11):1070-9. PubMed ID: 26172944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers.
    Hocke S; Guo Y; Job A; Orth M; Ziesch A; Lauber K; De Toni EN; Gress TM; Herbst A; Göke B; Gallmeier E
    Oncotarget; 2016 Feb; 7(6):7080-95. PubMed ID: 26755646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers.
    Jansen AM; van Wezel T; van den Akker BE; Ventayol Garcia M; Ruano D; Tops CM; Wagner A; Letteboer TG; Gómez-García EB; Devilee P; Wijnen JT; Hes FJ; Morreau H
    Eur J Hum Genet; 2016 Jul; 24(7):1089-92. PubMed ID: 26648449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exome sequencing reveals a de novo POLD1 mutation causing phenotypic variability in mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome (MDPL).
    Elouej S; Beleza-Meireles A; Caswell R; Colclough K; Ellard S; Desvignes JP; Béroud C; Lévy N; Mohammed S; De Sandre-Giovannoli A
    Metabolism; 2017 Jun; 71():213-225. PubMed ID: 28521875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas.
    Spier I; Holzapfel S; Altmüller J; Zhao B; Horpaopan S; Vogt S; Chen S; Morak M; Raeder S; Kayser K; Stienen D; Adam R; Nürnberg P; Plotz G; Holinski-Feder E; Lifton RP; Thiele H; Hoffmann P; Steinke V; Aretz S
    Int J Cancer; 2015 Jul; 137(2):320-31. PubMed ID: 25529843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.
    IJsselsteijn ME; Sanz-Pamplona R; Hermitte F; de Miranda NFCC
    Mol Aspects Med; 2019 Oct; 69():123-129. PubMed ID: 31136750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.